Regeneron (REGN) Webpage traffic Statistics 2025

318,000 1.7%

1M 1.6% 3M 3.2%

Est. monthly webpage visitors.

Similar companies

Company		Webpage traffic
	Amgen AMGN	478,000 11%
	Gilead Sciences GILD	462,000 13.3%
	Catalyst Pharmaceuticals CPRX	10,000 30.9%
	Inovio Pharmaceuticals INO	10,000 10.3%
	Anavex Life Sciences AVXL	11,000 21.6%

Month over Month

Est. monthly webpage visitors.

Aug 2025	318,000	1.6%
Jul 2025	313,000	29.8%
Jun 2025	446,000	44.8%
May 2025	308,000	20.8%
Apr 2025	255,000

How many visits regeneron.com?

Regeneron has an estimate of 318,000 visitors to regeneron.com in August. This is up since July.

Analyzing Webpage traffic, how is Regeneron performing compared to its industry peers?

Regeneron underperforms its industry peers when it comes to Webpage traffic, ranking in the 6th percentile.

Why is it important to track website traffic for Regeneron?

By staying updated on webpage traffic for Regeneron, investors can gain valuable insights into the company's digital performance, customer engagement and acquisition, and overall effectiveness of its online presence. Higher traffic can indicate greater visibility and potential customer exposure and a lower or decreasing traffic can indicate challenges with retaining customers.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.